Skip To Main Content
Pasquale Lombardi on Muck Rack

Pasquale Lombardi

As seen in: MDPI, BioRxiv, Lung Cancer, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Pasquale

Contact Pasquale, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

|
By Pasquale Lombardi, Erik Ramon-Gil, Leonardo Brunetti, Giulia Manfredi
| BioRxiv
New Results Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.
Open in Who Shared Issue with article?

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings

|
By Pasquale Lombardi, Marco Filetti, Rosa Falcone, Valeria Altamura
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessReview by Pasquale Lombardi 1, Marco Filetti 1,2, Rosa Falcone 1, Valeria Altamura 1, Francesco Paroni Sterbini 1, Emilio Bria 3,4, Alessandra Fabi 5, Diana Giannarelli 6, Giovanni Scambia 7,8 and Gennaro Daniele 1,* 1 Phase 1 Unit, Fondazione Policlinico Universitario A.
Open in Who Shared Issue with article?

Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study

|
By Laura Marandino, Federica Trastu, Eleonora Ghisoni, Pasquale Lombardi
| bmj.com
Discussion In this study, we showed that the proportion of randomised phase III trials that included QoL as a study endpoint has increased in recent years, though it remains suboptimal, particularly in trials promoted by academic sponsors. In many cases, although collected according to study protocol, QoL data are not presented in the primary publication.
Open in Who Shared Issue with article?
See all 8 articles